Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hy2Care Injectable hydrogel is an in-situ forming, biodegradable scaffold developed for the functional repair and regeneration of articular cartilage defects, specifically in the knee. The product consists of a polymer-based hydrogel (typically dextran and hyaluronic acid conjugates) that is injected into the cartilage defect during a surgical procedure. Once applied, it undergoes rapid enzymatic crosslinking to form a stable, biocompatible matrix that mimics the natural environment of cartilage, facilitating cell infiltration and the synthesis of new extracellular matrix. It is primarily indicated for patients with small focal cartilage lesions and is currently being evaluated in pivotal clinical trials to support CE marking and commercialization.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Hy2Care Injectable hydrogel.